Compound ID | 133
TD-1607
Class: Glycopeptide
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against Gram-positives causing acute bacterial skin and skin structure infections (ABSSSI), hospital-acquired pneumonia/ ventilator-associated pneumonia, and bacteraemia |
| Description: | A glycopeptide-cephalosporin heterodimer |
| Institute where first reported: | Theravance Biopharma, USA |
| Year first mentioned: | 2010 |
| Highest development stage: | Phase 1 (NCT01949103) |
| Development status: | Active |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.